Luna Diabetes Company Profile

Background

Overview

Luna Diabetes, founded in 2020, is a medical device company headquartered in San Diego, California. The company specializes in developing innovative solutions for diabetes management, focusing on enhancing nighttime glucose control for individuals using insulin pens. Their flagship product, Luna, is designed to automate insulin delivery during sleep, aiming to improve overall glucose control without the need for a traditional insulin pump.

Mission and Vision

Luna Diabetes is committed to simplifying diabetes management by providing accessible and effective solutions that integrate seamlessly into users' daily routines. Their vision is to empower individuals with diabetes to achieve better health outcomes through innovative technology that addresses the unique challenges of nighttime glucose control.

Industry Significance

The company operates within the medical device industry, specifically focusing on diabetes care. By introducing an automated insulin delivery system tailored for insulin pen users, Luna Diabetes addresses a significant gap in the market, offering a less invasive and more accessible alternative to traditional insulin pumps.

Key Strategic Focus

Core Objectives

Automated Insulin Delivery: Develop and refine systems that automate insulin dosing during sleep to enhance glucose control.

User Accessibility: Create devices that are easy to use and integrate with existing diabetes management tools, such as insulin pens and continuous glucose monitors (CGMs).

Cost-Effectiveness: Offer affordable solutions to make advanced diabetes management accessible to a broader population.

Areas of Specialization

Nighttime Glucose Control: Focusing on improving glucose regulation during sleep, a critical period for individuals with diabetes.

Integration with Insulin Pens: Designing devices that complement existing insulin pen usage without requiring a full transition to insulin pumps.

Key Technologies Utilized

Automated Insulin Delivery Systems: Utilizing algorithms to calculate and deliver micro-doses of insulin during sleep.

Continuous Glucose Monitoring (CGM) Integration: Ensuring compatibility with CGM systems to monitor glucose levels in real-time.

Primary Markets Targeted

Type 1 and Type 2 Diabetes Patients: Individuals who use insulin pens for diabetes management and seek improved nighttime glucose control.

Healthcare Providers: Endocrinologists and diabetes specialists interested in offering advanced management solutions to their patients.

Financials and Funding

Funding History

Luna Diabetes has successfully raised a total of $23.6 million through a Series A funding round completed in August 2025.

Notable Investors

Vensana Capital: A venture capital firm specializing in medical technology investments.

Swiss Diabetes Venture Fund: An investment fund focused on diabetes-related innovations.

Ascensia Diabetes Care: A global diabetes care company.

Winklevoss Capital: A venture capital firm investing in various technology sectors.

Utilization of Capital

The funds are intended to advance regulatory submissions, conduct clinical studies, build manufacturing capacity, and expand clinical and market access programs.

Pipeline Development

Key Pipeline Candidates

Luna Patch Pump: The primary product in development, designed to automate insulin delivery during sleep for insulin pen users.

Stages of Development

Clinical Trials: The company has initiated pivotal trials to evaluate the safety and effectiveness of the Luna system.

Target Conditions

Type 1 and Type 2 Diabetes: Focusing on individuals who require insulin therapy and seek improved glucose control during sleep.

Anticipated Milestones

Regulatory Approval: Seeking FDA clearance for the Luna system.

Market Launch: Plans to introduce the product to the market upon successful completion of clinical trials and regulatory processes.

Technological Platform and Innovation

Proprietary Technologies

Closed-Loop Insulin Dosing Algorithm: A unique algorithm that automates insulin delivery based on real-time glucose data.

Significant Scientific Methods

Automated Insulin Delivery Systems: Utilizing advanced algorithms to manage insulin dosing during sleep.

Integration with CGM Systems: Ensuring seamless data exchange between the Luna device and CGMs for accurate glucose monitoring.

Leadership Team

Key Executives

John Sjölund: Co-founder and CEO. Previously co-founded Timesulin and served as VP of connected injection systems at Bigfoot Biomedical.

Jon Brilliant: Co-founder and CFO. Co-founded Bigfoot Biomedical and has extensive experience in financial management within the medical device sector.

Sean Saint: Co-founder and Board Member. CEO of Beta Bionics, bringing expertise in insulin delivery systems.

Competitor Profile

Market Insights and Dynamics

The diabetes management market is evolving, with a growing emphasis on personalized and automated solutions. The demand for devices that integrate with existing tools like insulin pens and CGMs is increasing, presenting opportunities for companies like Luna Diabetes.

Competitor Analysis

Beta Bionics: Develops the iLet Bionic Pancreas System, a fully automated insulin delivery system.

Medtronic: Offers the MiniMed series of insulin pumps with integrated CGM systems.

Tandem Diabetes Care: Provides the t:slim X2 insulin pump with Basal-IQ technology.

Strategic Collaborations and Partnerships

Luna Diabetes has partnered with Ascensia Diabetes Care to enhance the integration of their devices with CGM systems, aiming to provide a more comprehensive solution for diabetes management.

Operational Insights

Strategic Considerations

Luna Diabetes differentiates itself by focusing on nighttime glucose control for insulin pen users, a segment often overlooked by traditional insulin pump manufacturers. This strategic focus allows the company to address a significant unmet need in the market.

Competitive Advantages

User-Friendly Design: The Luna system is designed for easy integration with existing diabetes management routines.

Cost Accessibility: By offering a less invasive and more affordable alternative to traditional insulin pumps, Luna Diabetes makes advanced diabetes management more accessible.

Strategic Opportunities and Future Directions

Strategic Roadmap

Product Development: Continue refining the Luna system based on clinical trial feedback.

Regulatory Approval: Achieve FDA clearance to bring the product to market.

Market Expansion: Expand distribution channels to reach a broader audience of insulin pen users.

Future Business Directions

Luna Diabetes plans to explore additional product offerings that complement the Luna system, such as mobile applications for data tracking and analysis, to provide a comprehensive solution for diabetes management.